Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer

Published:2020-01 Issue:1 Volume:20 Page:101-109
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

McCleary-Wheeler Angela L.,Carr Ryan M.,Palmer Shanique R.,Smyrk Thomas C.,Allred Jacob B.,Almada Luciana L.,Tolosa Ezequiel J.,Lamberti Maria J.,Marks David L.,Borad Mitesh J.,Molina Julian R.,Qi Yingwei,Lingle Wilma L.,Grothey Axel,Pitot Henry C.,Jatoi Aminah,Northfelt Donald W.,Bryce Alan H.,McWilliams Robert R.,Okuno Scott H.,Haluska Paul,Kim George P.,Colon-Otero Gerardo,Lowe Val J.,Callstrom Matthew R.,Ma Wen We,Bekaii-Saab Tanios,Hung Mien-Chie^ORCID,Erlichman Charles,Fernandez-Zapico Martin E.

Funder

Mayo Clinic Pancreatic Cancer

SPORE

Kellen Foundation

Georgeson Professorship fund

Mayo Clinic Cancer Center

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference51 articles.

1. Cancer statistics, 2019;Siegel;CA A Cancer J Clin,2019

2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver and pancreas cancers in the United States;Rahib;Cancer Res,2014

3. Therapeutic antibodies for the treatment of pancreatic cancer;Chames;Sci World J,2010

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol: Off J Am Soc Clin Oncol,1997

5. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale;Colucci;Cancer,2002

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Status of Hedgehog Signaling Inhibitors;Current Topics in Medicinal Chemistry;2024-01

2. Recent advances in targeted therapy for pancreatic adenocarcinoma;World Journal of Gastrointestinal Oncology;2023-04-15

3. Signaling pathways in the regulation of cancer stem cells and associated targeted therapy;MedComm;2022-10-05

4. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer;Critical Reviews in Oncology/Hematology;2022-08

5. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma;Pharmacology & Therapeutics;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3